Product name: Semaglutide
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(aka DC18-Gamma-Glu-PEG2-PEG2)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Catalog #: 3902011
CAS No.: 910463-68-2
Molecular Formula: C187H291N45O59
Molecular Weight: 4113.64
Description: Semaglutide is to date the last one in the list of GLP-1 mimetics which are under clinical assessment. Three minor but important modifications make semaglutide suitable for clinical use: amino acid substitutions at position 8 (alanine to alpha-aminoisobutyric acid, a synthetic amino acid) and position 34 (lysine to arginine), and acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain to lysine at position 26. The fatty di-acid side chain and the spacer mediate strong binding to albumin, which is believed to result in reduced renal clearance. Semaglutide (marketed as Ozempic®) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of T2DM. Semaglutide also reduces the risk of major cardiovascular events and decreases appetite and food intake, therefore becoming an interesting drug to be used in obese patients.